Regeneron has announced that the European Commission (EC) has approved Libtayo (cemiplimab) as a monotherapy for the treatment of adult patients with second-line recurrent or metastatic cervical ...

Regeneron also purchased rights to the collaboration's PD-1 antibody Libtayo, which could serve as a foundation for future oncology combination regimens. Eylea has become the leading franchise in ...

Regeneron aims to advance cancer treatments through innovative research and partnerships while emphasizing the significance of their PD-1 inhibitor, Libtayo, in ongoing clinical trials.

Regeneron continues to deliver growth on top/bottom line in the near to longer-term with Dupi and Libtayo, the analyst tells investors in a research note.

Meanwhile, Regeneron is also looking to diversify its revenue base to reduce its dependence on Eylea for top-line growth and build an oncology franchise, which currently comprises Libtayo.

Regeneron Pharmaceuticals ... injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma ...

Sales of oncology drug, Libtayo, also missed estimates. Shares are trading down in response to lower-than-expected results. Regeneron’s shares have lost 14.1% year to date compared with the ...

Shares of Regeneron Pharmaceuticals (NASDAQ ... The standard version of the anti-VEGF intravitreal injection delivered $1.4B in net product sales for the company in Q1, indicating a ~29% YoY ...